Targeting promiscuous signaling pathways in cancer: Another Notch in the bedpost

Trends in Molecular Medicine

Volumn 10, Issue 12, 2004, Pages 591-598

  Beverly, Levi J ^a   Capobianco, Anthony J ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; BUSULFAN; HYDROXYUREA; IK PROTEIN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH RECEPTOR; PROTEIN DERIVATIVE; RECOMBINANT ALPHA INTERFERON; RITUXIMAB; ROSCOVITINE; TRANSCRIPTION FACTOR ETS; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APOPTOSIS; B CELL LEUKEMIA; CANCER; CANCER SURVIVAL; CARCINOGENESIS; CHIMERA; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CORRELATION ANALYSIS; DNA BINDING; DRUG EFFECT; GENE DISRUPTION; GENE MUTATION; GENE REPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GRAFT REJECTION; HUMAN; LEUKEMOGENESIS; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; MUTAGENESIS; NONHUMAN; PROTEIN PROTEIN INTERACTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION INITIATION; ZINC FINGER MOTIF;

DNA-BINDING PROTEINS; DRUG DESIGN; HUMANS; IKAROS TRANSCRIPTION FACTOR; LEUKEMIA, T-CELL, ACUTE; MEMBRANE PROTEINS; RECEPTOR, NOTCH1; RECEPTORS, CELL SURFACE; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 9644273898     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.10.001     Document Type: Review

References (72)

1. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
2. O.P. Mgbonyebi Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells Cancer Res. 59 1999 1903 1910
3. J. Li Leukaemia disease genes: large-scale cloning and pathway predictions Nat. Genet. 23 1999 348 353
4. J. Jonkers, and A. Berns Retroviral insertional mutagenesis as a strategy to identify cancer genes Biochim. Biophys. Acta 1287 1996 29 57
5. H. Mikkers, and A. Berns Retroviral insertional mutagenesis: tagging cancer pathways Adv. Cancer Res. 88 2003 53 99
6. R. Kim Genome-based identification of cancer genes by proviral tagging in mouse retrovirus-induced T-cell lymphomas J. Virol. 77 2003 2056 2062
7. H. Mikkers High-throughput retroviral tagging to identify components of specific signaling pathways in cancer Nat. Genet. 32 2002 153 159
8. L. Chin Essential role for oncogenic Ras in tumour maintenance Nature 400 1999 468 472
9. C.S. Huettner Reversibility of acute B-cell leukaemia induced by BCR-ABL1 Nat. Genet. 24 2000 57 60
10. D.W. Felsher, and J.M. Bishop Reversible tumorigenesis by MYC in hematopoietic lineages Mol. Cell 4 1999 199 207
11. C.M. D'Cruz c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations Nat. Med. 7 2001 235 239
12. C.M. Eischen Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis Genes Dev. 13 1999 2658 2669
13. K.H. Maclean c-Myc augments γ-irradiation-induced apoptosis by suppressing Bcl-XL Mol. Cell. Biol. 23 2003 7256 7270
14. L.W. Ellisen TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms Cell 66 1991 649 661
15. J.S. Mumm, and R. Kopan Notch signaling: from the outside in Dev. Biol. 228 2000 151 165
16. E.C. Lai Keeping a good pathway down: transcriptional repression of Notch pathway target genes by CSL proteins EMBO Rep. 3 2002 840 845
17. J.C. Aster, and W.S. Pear Notch signaling in leukemia Curr. Opin. Hematol. 8 2001 237 244
18. K. Georgopoulos The Ikaros gene is required for the development of all lymphoid lineages Cell 79 1994 143 156
19. K. Hahm The lymphoid transcription factor LyF-1 is encoded by specific, alternatively spliced mRNAs derived from the Ikaros gene Mol. Cell. Biol. 14 1994 7111 7123
20. A. Molnar, and K. Georgopoulos The Ikaros gene encodes a family of functionally diverse zinc finger DNA-binding proteins Mol. Cell. Biol. 14 1994 8292 8303
21. A.S. McCarty Selective dimerization of a C2H2 zinc finger subfamily Mol. Cell 11 2003 459 470
22. L. Sun Zinc finger-mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development EMBO J. 15 1996 5358 5369
23. S. Winandy A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma Cell 83 1995 289 299
24. L. Sun Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia J. Clin. Oncol. 17 1999 3753 3766
25. Y. Hosokawa The Ikaros gene, a central regulator of lymphoid differentiation, fuses to the BCL6 gene as a result of t(3;7)(q27;p12) translocation in a patient with diffuse large B-cell lymphoma Blood 95 2000 2719 2721
26. S. Yoshida Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas: 5′-RACE and LA - PCR analyses of biopsy samples Oncogene 18 1999 7994 7999
27. H. Nakayama Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia Cancer Res. 59 1999 3931 3934
28. IC- induced T cell leukemogenesis Cancer Cell 3 2003 551 564
29. B.S. Cobb Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding Genes Dev. 14 2000 2146 2160
30. J. Kim Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes Immunity 10 1999 345 355
31. J. Koipally, and K. Georgopoulos Ikaros interactions with CtBP reveal a repression mechanism that is independent of histone deacetylase activity J. Biol. Chem. 275 2000 19594 19602
32. + thymocytes by Ikaros proteins in direct competition with an Ets activator Genes Dev. 15 2001 1817 1832
33. S. Dovat A common mechanism for mitotic inactivation of C2H2 zinc finger DNA-binding domains Genes Dev. 16 2002 2985 2990
34. P. Gomez-del Arco Phosphorylation controls Ikaros's ability to negatively regulate the G(1)-S transition Mol. Cell. Biol. 24 2004 2797 2807
35. Lopez-Nieva, P. et al. (2004) Altered expression of Notch1, Notch2, c-Myc and Ikaros in γ-radiation induced mouse thymic lymphomas. Carcinogenesis
36. Q. Li, and I.M. Verma NF-κB regulation in the immune system Nat. Rev. Immunol. 2 2002 725 734
37. J. Ruland, and T.W. Mak Transducing signals from antigen receptors to nuclear factor κB Immunol. Rev. 193 2003 93 100
38. J. Kucharczak To be, or not to be: NF-κB is the answer - role of Rel/NF-κB in the regulation of apoptosis Oncogene 22 2003 8961 8982
39. M.W. Mayo Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras Science 278 1997 1812 1815
40. H. Jo NF-κB is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis Oncogene 19 2000 841 849
41. J.Y. Reuther A requirement for NF-κB activation in Bcr-Abl-mediated transformation Genes Dev. 12 1998 968 981
42. F. Oswald NF-κB2 is a putative target gene of activated Notch-1 via RBP-Jκ Mol. Cell. Biol. 18 1998 2077 2088
43. F. Oakley Basal expression of IκBα is controlled by the mammalian transcriptional repressor RBP-J (CBF1) and its activator Notch1 J. Biol. Chem. 278 2003 24359 24370
44. M. Rohrbaugh Notch activation of yan expression is antagonized by RTK/pointed signaling in the Drosophila eye Curr. Biol. 12 2002 576 581
45. C. Kannabiran The mammalian transcriptional repressor RBP (CBF1) regulates interleukin-6 gene expression Mol. Cell. Biol. 17 1997 1 9
46. M. Palmieri Interaction of the nuclear protein CBF1 with the κB site of the IL-6 gene promoter Nucleic Acids Res. 27 1999 2785 2791
47. S.H. Lee Functional interactions between an atypical NF-κB site from the rat CYP2B1 promoter and the transcriptional repressor RBP-Jκ/CBF1 Nucleic Acids Res. 28 2000 2091 2098
48. D. Leprince A putative second cell-derived oncogene of the avian leukaemia retrovirus E26 Nature 306 1983 395 397
49. T. Oikawa, and T. Yamada Molecular biology of the Ets family of transcription factors Gene 303 2003 11 34
50. A.D. Sharrocks The ETS-domain transcription factor family Nat. Rev. Mol. Cell Biol. 2 2001 827 837
51. F. Moreau-Gachelin Spi-1/PU.1 transgenic mice develop multistep erythroleukemias Mol. Cell. Biol. 16 1996 2453 2463
52. F. Moreau-Gachelin Spi-1/PU.1: an oncogene of the Ets family Biochim. Biophys. Acta 1198 1994 149 163
53. A. Buijs Translocation (12;22)(p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11 Oncogene 10 1995 1511 1519
54. A. Buijs The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity Mol. Cell. Biol. 20 2000 9281 9293
55. S. Jeffries Characterization of a high-molecular-weight Notch complex in the nucleus of Notch(ic)-transformed RKE cells and in a human T-cell leukemia cell line Mol. Cell. Biol. 22 2002 3927 3941
56. M. Kitagawa A human protein with sequence similarity to Drosophila mastermind coordinates the nuclear form of notch and a CSL protein to build a transcriptional activator complex on target promoters Mol. Cell. Biol. 21 2001 4337 4346
57. L. Wu MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors Nat. Genet. 26 2000 484 489
58. A.P. Weng Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling Mol. Cell. Biol. 23 2003 655 664
59. L.T. Vassilev In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848
60. D. Slamon, and M. Pegram Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials Semin Oncol 28 Suppl. 3 2001 13 19
61. E.L. Sievers Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate Blood 93 1999 3678 3684
62. S.J. Hotte, and H.W. Hirte BAY 43-9006: early clinical data in patients with advanced solid malignancies Curr. Pharm. Des. 8 2002 2249 2253
63. J. Baselga Phase I and II clinical trials of trastuzumab Ann. Oncol 12 Suppl. 1 2001 S49 S55
64. J.D. Rowley Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia Ann. Genet. 16 1973 109 112
65. P.C. Nowell, and D.A. Hungerford Chromosome studies on normal and leukemic human leukocytes J. Natl. Cancer Inst. 25 1960 85 109
66. R.P. Gale Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group Blood 91 1998 1810 1819
67. R.T. Silver An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology Blood 94 1999 1517 1536
68. T. Schindler Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289 2000 1938 1942
69. B.J. Druker Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 344 2001 1031 1037
70. B.J. Druker Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N. Engl. J. Med. 344 2001 1038 1042
71. M.E. Gorre Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880
72. P. La Rosee Activity of the BCR-ABL kinase inhibitor PD180970 against clinically relevant BCR-ABL isoforms that cause resistance to imatinib mesylate (Gleevec, STI571) Cancer Res. 62 2002 7149 7153